Table 1.

Antiviral activities of the test compounds against tobacco mosaic virus (TMV) in vivo at 500 μg/mL.

Compd.	Curative Activity (%) a	Protection Activity (%) a	Inactivation Activity (%) a
M1	52.5 ± 5.2	60.7 ± 4.3	65.4 ± 2.9
M2	47.7 ± 4.3	68.6 ± 7.7	82.1 ± 4.1
M3	42.1 ± 6.1	57.4 ± 2.4	63.4 ± 6.8
M4	45.3 ± 2.3	50.2 ± 2.2	83.2 ± 4.4
M5	29.8 ± 4.2	59.3 ± 5.9	63.9 ± 6.1
M6	48.3 ± 3.3	72.3 ± 5.2	79.6 ± 3.4
M7	43.2 ± 6.7	56.3 ± 4.6	66.1 ± 5.0
M8	45.1 ± 6.6	51.1 ± 4.2	85.6 ± 2.6
M9	43.2 ± 3.5	49.4 ± 5.2	75.2 ± 3.8
M10	46.5 ± 5.6	62.2 ± 2.1	85.1 ± 3.6
M11	42.4 ± 4.3	57.3 ± 3.6	71.5 ± 5.1
M12	38.4 ± 4.5	57.6 ± 1.2	66.0 ± 2.8
M13	46.2 ± 5.8	51.8 ± 5.5	70.8 ± 2.7
M14	46.5 ± 3.7	62.3 ± 6.2	83.6 ± 2.3
M15	38.7 ± 6.2	52.8 ± 4.7	62.9 ± 6.0
M16	38.5 ± 4.3	48.3 ± 5.2	57.3 ± 3.5
M17	46.3 ± 4.3	57.4 ± 5.1	61.5 ± 3.2
M18	45.7 ± 3.8	61.3 ± 4.5	66.4 ± 4.2
M19	41.2 ± 6.2	60.3 ± 3.5	65.6 ± 4.7
M20	41.2 ± 3.2	47.3 ± 4.1	63.6 ± 4.3
M21	45.2 ± 6.2	55.6 ± 6.1	60.3 ± 5.9
Ribavirin	37.9 ± 1.9	51.8 ± 2.3	72.9 ± 2.4

^a: Average of three replicates.